Developing Innovative
Best-in-Class Vaccines
Computationally Designed VLP Vaccines
By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.
RSV, hMPV, and SARS-CoV-2 Vaccines
Our vaccine candidates for respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, have the potential to induce high neutralizing antibody titers for more effective protection.
